United Therapeutics Corporation
United Therapeutics Announces $2 Billion Stock Repurchase Program
Summary
United Therapeutics Corporation announced that its Board of Directors has authorized a new stock repurchase program of up to $2 billion over the next year. The company has entered into accelerated share repurchase (ASR) agreements with Citibank, N.A. for an initial $1.5 billion. The remaining $500 million will be available for additional repurchases over the next year. The ASR agreements include a $750 million uncollared agreement and a $750 million collared agreement, with an upfront payment of $1.5 billion to be made by United Therapeutics to Citibank on or around March 11, 2026. The final number of shares repurchased will be based on the average volume-weighted average price per share during the term of the agreements, subject to certain adjustments. The uncollared ASR is scheduled to terminate in the second quarter of 2026, and the collared ASR in the third quarter of 2026. At final settlement, United Therapeutics may receive additional shares or be required to make a cash payment to Citibank or deliver shares, depending on the circumstances.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement